S100A12 and rheumatic disorder: Prior research shows that S100 proteins [11], specifically S100A8/9 (formerly MRP8/14 or calprotectin) and S100A12 (formerly calgranulin C or EN-RAGE), may be predictive biomarkers of treatment response in rheumatic diseases, including pJIA [12–14].